Compound Evidence File
#EC-2026-0685
APAAN (alpha-phenylacetoacetonitrile) CAS 4468-48-8
Filed under Raw Materials. The bureau holds 116 laboratory returns for this compound from 34 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
34 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 7 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 10.0 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 10.0 | 10.0 | 5 Mar 2026 | 2 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 10.0 | 10.0 | 7 Nov 2025 | 14 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 17 Nov 2025 | 1 May 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 10.0 | 10.0 | 4 Jan 2026 | 12 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 10.0 | 10.0 | 21 Apr 2026 | 15 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 10.0 | 10.0 | 10.0 | 1 May 2026 | 3 Aug 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 9.9 | 10.0 | 15 Apr 2026 | 8 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 10.0 | 10.0 | 10.0 | 12 Jun 2026 | 6 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 19 Apr 2026 | 17 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 28 Nov 2025 | 8 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 9.9 | 22 Dec 2025 | 17 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 8 Apr 2026 | 27 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 20 Dec 2025 | 10 Aug 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 10.0 | 17 Dec 2025 | 2 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 9.9 | 9.9 | 9.9 | 25 Dec 2025 | 9 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 12 Mar 2026 | 25 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 7 Mar 2026 | 28 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Mar 2026 | 8 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 9.9 | 6 May 2026 | 23 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 6 Apr 2026 | 3 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 3 Aug 2026 | 9 Aug 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 5 | 9.0 | 7.8 | 9.8 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 6 | 8.5 | 6.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 8.4 | 7.3 | 9.2 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.2 | 6.9 | 9.7 | 21 May 2026 | 21 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 8.0 | 7.0 | 9.3 | 23 May 2026 | 23 May 2026 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | X | 4 | 7.5 | 5.7 | 8.6 | 11 Jun 2025 | 19 Jan 2026 |
| Xingtai Pukelai Technology CoCASE #VI-2026-0850 | X | 1 | 7.5 | 7.5 | 7.5 | 2 Jul 2025 | 2 Jul 2025 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 6 | 7.1 | 3.7 | 9.6 | 2 Apr 2025 | 24 May 2026 |
| PeptiSlimCASE #VI-2026-0557 | X | 1 | 7.0 | 7.0 | 7.0 | 7 May 2025 | 7 May 2025 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 6.9 | 6.9 | 6.9 | 20 Jun 2025 | 20 Jun 2025 |
| Amino LairCASE #VI-2026-0413 | X | 1 | 6.9 | 6.9 | 6.9 | 8 Jul 2025 | 8 Jul 2025 |
Open any subject to view the batch-level evidence for APAAN (alpha-phenylacetoacetonitrile) CAS 4468-48-8 alone.